BioLineRx is a late clinical-stage biopharmaceutical development company that focuses on oncology.
BioLineRx is a clinical-stage, publicly traded (NASDAQ/ TASE: BLRX) biopharmaceutical development company based in Jerusalem, Israel. The Company develops products suitable for the pharmaceutical market satisfying an unmet medical need or exhibiting advantages over current therapies.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Sep 15, 2022 | Post-IPO Debt | $10M | 1 |
Kreos Capital
|
— | Detail |
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Kreos Capital
|
Yes | Post-IPO Debt |